Lv727
4710 积分 2023-01-10 加入
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
13天前
已完结
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
1个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
1个月前
已完结
Long-Term Safety of “4-Hour” Hemoadsorption Combined with Hemodialysis in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study
2个月前
已完结
Efficacy of HA130 Hemoadsorption in Removing Advanced Glycation End Products in Maintenance Hemodialysis Patients
2个月前
已完结
Hemoadsorption combined with hemodialysis versus hemodialysis alone on mortality in end-stage kidney disease: a randomized, open-label, multicenter trial
2个月前
已关闭
Elevated serum levels of soluble adhesion molecules predict death in pre‐dialysis patients: association with malnutrition, inflammation, and cardiovascular disease
2个月前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
2个月前
已完结
Time to establish a consensus definition of clinical remission distinct from well-controlled asthma
2个月前
已关闭
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer
2个月前
已完结
皖公网安备34019202002308
